Entering text into the input field will update the search result below

Ocular stock rises as eye drug implant OTX-TKI shows promise in vision disorder in trial

Aged female eye with wrinkled skin

Jun

Ocular Therapeutix (NASDAQ:OCUL) said its eye implant OTX-TKI was seen to be safe and well tolerated in patients as per interim 7-month data from a U.S. phase 1 trial to treat wet age-related macular degeneration (wet AMD).

The

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
PFE
--
OCUL
--